ID   VIP2_HUMAN              Reviewed;        1243 AA.
AC   O43314; A1NI53; A6NGS8; Q8TB50;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   15-JAN-2008, sequence version 3.
DT   10-MAY-2017, entry version 130.
DE   RecName: Full=Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 2;
DE            EC=2.7.4.21 {ECO:0000269|PubMed:21222653};
DE            EC=2.7.4.24 {ECO:0000269|PubMed:21222653};
DE   AltName: Full=Diphosphoinositol pentakisphosphate kinase 2;
DE   AltName: Full=Histidine acid phosphatase domain-containing protein 1;
DE   AltName: Full=InsP6 and PP-IP5 kinase 2;
DE   AltName: Full=VIP1 homolog 2;
DE            Short=hsVIP2;
GN   Name=PPIP5K2; Synonyms=HISPPD1, KIAA0433, VIP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=9455477; DOI=10.1093/dnares/4.5.307;
RA   Ishikawa K., Nagase T., Nakajima D., Seki N., Ohira M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VIII.
RT   78 new cDNA clones from brain which code for large proteins in
RT   vitro.";
RL   DNA Res. 4:307-313(1997).
RN   [2]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, ENZYME ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=17690096; DOI=10.1074/jbc.M704656200;
RA   Fridy P.C., Otto J.C., Dollins D.E., York J.D.;
RT   "Cloning and characterization of two human VIP1-like inositol
RT   hexakisphosphate and diphosphoinositol pentakisphosphate kinases.";
RL   J. Biol. Chem. 282:30754-30762(2007).
RN   [7]
RP   FUNCTION, AND ENZYME ACTIVITY.
RX   PubMed=17702752; DOI=10.1074/jbc.M704655200;
RA   Choi J.H., Williams J., Cho J., Falck J.R., Shears S.B.;
RT   "Purification, sequencing, and molecular identification of a mammalian
RT   PP-InsP5 kinase that is activated when cells are exposed to
RT   hyperosmotic stress.";
RL   J. Biol. Chem. 282:30763-30775(2007).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1006; SER-1016 AND
RP   SER-1172, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-38, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   CATALYTIC ACTIVITY, AND POLYPHOSPHOINOSITIDE-BINDING DOMAIN.
RX   PubMed=21222653; DOI=10.1042/BJ20101437;
RA   Gokhale N.A., Zaremba A., Shears S.B.;
RT   "Receptor-dependent compartmentalization of PPIP5K1, a kinase with a
RT   cryptic polyphosphoinositide binding domain.";
RL   Biochem. J. 434:415-426(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-38; SER-223; SER-1006;
RP   SER-1016; SER-1074; SER-1091; SER-1165; SER-1172; SER-1180; SER-1220
RP   AND SER-1221, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-38; SER-1006 AND
RP   SER-1091, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14] {ECO:0000244|PDB:3T54, ECO:0000244|PDB:3T7A, ECO:0000244|PDB:3T99, ECO:0000244|PDB:3T9A, ECO:0000244|PDB:3T9B, ECO:0000244|PDB:3T9C, ECO:0000244|PDB:3T9D, ECO:0000244|PDB:3T9E, ECO:0000244|PDB:3T9F}
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 41-366 IN COMPLEXES WITH
RP   ATP; SUBSTRATE AND TRANSITION STATE ANALOG, AND MUTAGENESIS OF
RP   ARG-213; LYS-248 AND ARG-262.
RX   PubMed=22119861; DOI=10.1038/nchembio.733;
RA   Wang H., Falck J.R., Hall T.M., Shears S.B.;
RT   "Structural basis for an inositol pyrophosphate kinase surmounting
RT   phosphate crowding.";
RL   Nat. Chem. Biol. 8:111-116(2012).
CC   -!- FUNCTION: Bifunctional inositol kinase that acts in concert with
CC       the IP6K kinases IP6K1, IP6K2 and IP6K3 to synthesize the
CC       diphosphate group-containing inositol pyrophosphates
CC       diphosphoinositol pentakisphosphate, PP-InsP5, and bis-
CC       diphosphoinositol tetrakisphosphate, (PP)2-InsP4. PP-InsP5 and
CC       (PP)2-InsP4, also respectively called InsP7 and InsP8, regulate a
CC       variety of cellular processes, including apoptosis, vesicle
CC       trafficking, cytoskeletal dynamics, exocytosis, insulin signaling
CC       and neutrophil activation. Phosphorylates inositol
CC       hexakisphosphate (InsP6) at positions 1 or 3 to produce PP-InsP5
CC       which is in turn phosphorylated by IP6Ks to produce (PP)2-InsP4.
CC       Alternatively, phosphorylates at position 1 or 3 PP-InsP5,
CC       produced by IP6Ks from InsP6, to produce (PP)2-InsP4.
CC       {ECO:0000269|PubMed:17690096, ECO:0000269|PubMed:17702752}.
CC   -!- CATALYTIC ACTIVITY: ATP + 1D-myo-inositol hexakisphosphate = ADP +
CC       1D-myo-inositol 5-diphosphate 1,2,3,4,6-pentakisphosphate.
CC       {ECO:0000269|PubMed:21222653}.
CC   -!- CATALYTIC ACTIVITY: ATP + 1D-myo-inositol 1-diphosphate 2,3,4,5,6-
CC       pentakisphosphate = ADP + 1D-myo-inositol 1,5-bis(diphosphate)
CC       2,3,4,6-tetrakisphosphate. {ECO:0000269|PubMed:21222653}.
CC   -!- CATALYTIC ACTIVITY: ATP + 1D-myo-inositol 5-diphosphate 1,2,3,4,6-
CC       pentakisphosphate = ADP + 1D-myo-inositol 1,5-bis(diphosphate)
CC       2,3,4,6-tetrakisphosphate. {ECO:0000269|PubMed:21222653}.
CC   -!- CATALYTIC ACTIVITY: ATP + 1D-myo-inositol hexakisphosphate = ADP +
CC       1D-myo-inositol 1-diphosphate 2,3,4,5,6-pentakisphosphate.
CC       {ECO:0000269|PubMed:21222653}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.13 uM for InsP6 {ECO:0000269|PubMed:17690096};
CC         KM=0.19 uM for InsP7 {ECO:0000269|PubMed:17690096};
CC         Vmax=0.39 nmol/min/mg enzyme with InsP6 as substrate
CC         {ECO:0000269|PubMed:17690096};
CC         Vmax=1.38 nmol/min/mg enzyme with InsP7 as substrate
CC         {ECO:0000269|PubMed:17690096};
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol
CC       {ECO:0000269|PubMed:17690096}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O43314-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O43314-2; Sequence=VSP_030636;
CC         Note=No experimental confirmation available.;
CC   -!- DOMAIN: The C-terminal acid phosphatase-like domain binds
CC       PtdIns(3,4,5)P3 and InsP6. Despite its similarity with the
CC       phosphatase domain of histidine acid phosphatases, it has no
CC       phosphatase activity. {ECO:0000305|PubMed:21222653}.
CC   -!- SIMILARITY: Belongs to the histidine acid phosphatase family. VIP1
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA24863.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=EAW49076.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB007893; BAA24863.2; ALT_INIT; mRNA.
DR   EMBL; AC011362; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471086; EAW49076.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; BC024591; AAH24591.1; -; mRNA.
DR   CCDS; CCDS34207.1; -. [O43314-2]
DR   CCDS; CCDS64212.1; -. [O43314-1]
DR   RefSeq; NP_001263206.1; NM_001276277.2. [O43314-1]
DR   RefSeq; NP_001268400.1; NM_001281471.2.
DR   RefSeq; NP_056031.2; NM_015216.4. [O43314-2]
DR   UniGene; Hs.212046; -.
DR   PDB; 3T54; X-ray; 1.90 A; A=37-366.
DR   PDB; 3T7A; X-ray; 1.70 A; A=41-366.
DR   PDB; 3T99; X-ray; 2.10 A; A=37-366.
DR   PDB; 3T9A; X-ray; 1.80 A; A=41-366.
DR   PDB; 3T9B; X-ray; 1.85 A; A=41-366.
DR   PDB; 3T9C; X-ray; 1.90 A; A=41-366.
DR   PDB; 3T9D; X-ray; 1.85 A; A=41-366.
DR   PDB; 3T9E; X-ray; 1.90 A; A=41-366.
DR   PDB; 3T9F; X-ray; 2.00 A; A=41-366.
DR   PDB; 4HN2; X-ray; 1.90 A; A=41-366.
DR   PDB; 4NZM; X-ray; 2.00 A; A=41-366.
DR   PDB; 4NZN; X-ray; 1.75 A; A=41-366.
DR   PDB; 4NZO; X-ray; 1.90 A; A=41-366.
DR   PDB; 4Q4C; X-ray; 1.90 A; A=41-366.
DR   PDB; 4Q4D; X-ray; 1.85 A; A=41-366.
DR   PDB; 5BYA; X-ray; 1.90 A; A=41-366.
DR   PDB; 5BYB; X-ray; 2.30 A; A=41-366.
DR   PDB; 5DGH; X-ray; 2.10 A; A=41-366.
DR   PDB; 5DGI; X-ray; 1.85 A; A=41-366.
DR   PDBsum; 3T54; -.
DR   PDBsum; 3T7A; -.
DR   PDBsum; 3T99; -.
DR   PDBsum; 3T9A; -.
DR   PDBsum; 3T9B; -.
DR   PDBsum; 3T9C; -.
DR   PDBsum; 3T9D; -.
DR   PDBsum; 3T9E; -.
DR   PDBsum; 3T9F; -.
DR   PDBsum; 4HN2; -.
DR   PDBsum; 4NZM; -.
DR   PDBsum; 4NZN; -.
DR   PDBsum; 4NZO; -.
DR   PDBsum; 4Q4C; -.
DR   PDBsum; 4Q4D; -.
DR   PDBsum; 5BYA; -.
DR   PDBsum; 5BYB; -.
DR   PDBsum; 5DGH; -.
DR   PDBsum; 5DGI; -.
DR   ProteinModelPortal; O43314; -.
DR   SMR; O43314; -.
DR   BioGrid; 116864; 11.
DR   IntAct; O43314; 5.
DR   STRING; 9606.ENSP00000313070; -.
DR   iPTMnet; O43314; -.
DR   PhosphoSitePlus; O43314; -.
DR   EPD; O43314; -.
DR   MaxQB; O43314; -.
DR   PaxDb; O43314; -.
DR   PeptideAtlas; O43314; -.
DR   PRIDE; O43314; -.
DR   Ensembl; ENST00000321521; ENSP00000313070; ENSG00000145725. [O43314-2]
DR   Ensembl; ENST00000358359; ENSP00000351126; ENSG00000145725. [O43314-1]
DR   Ensembl; ENST00000414217; ENSP00000416016; ENSG00000145725. [O43314-2]
DR   GeneID; 23262; -.
DR   KEGG; hsa:23262; -.
DR   UCSC; uc003kod.6; human. [O43314-1]
DR   CTD; 23262; -.
DR   DisGeNET; 23262; -.
DR   GeneCards; PPIP5K2; -.
DR   H-InvDB; HIX0005068; -.
DR   H-InvDB; HIX0029534; -.
DR   HGNC; HGNC:29035; PPIP5K2.
DR   HPA; HPA037895; -.
DR   HPA; HPA038442; -.
DR   MIM; 611648; gene.
DR   neXtProt; NX_O43314; -.
DR   OpenTargets; ENSG00000145725; -.
DR   PharmGKB; PA165660454; -.
DR   eggNOG; KOG1057; Eukaryota.
DR   eggNOG; ENOG410XNSN; LUCA.
DR   GeneTree; ENSGT00390000009048; -.
DR   HOGENOM; HOG000177917; -.
DR   HOVERGEN; HBG108657; -.
DR   InParanoid; O43314; -.
DR   KO; K13024; -.
DR   PhylomeDB; O43314; -.
DR   TreeFam; TF313594; -.
DR   BRENDA; 2.7.4.21; 2681.
DR   BRENDA; 2.7.4.24; 2681.
DR   Reactome; R-HSA-1855167; Synthesis of pyrophosphates in the cytosol.
DR   ChiTaRS; PPIP5K2; human.
DR   GenomeRNAi; 23262; -.
DR   PRO; PR:O43314; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000145725; -.
DR   CleanEx; HS_HISPPD1; -.
DR   ExpressionAtlas; O43314; baseline and differential.
DR   Genevisible; O43314; HS.
DR   GO; GO:0005829; C:cytosol; IDA:MGI.
DR   GO; GO:0003993; F:acid phosphatase activity; IEA:InterPro.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0033857; F:diphosphoinositol-pentakisphosphate kinase activity; IDA:MGI.
DR   GO; GO:0000829; F:inositol heptakisphosphate kinase activity; IBA:GO_Central.
DR   GO; GO:0052723; F:inositol hexakisphosphate 1-kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0052724; F:inositol hexakisphosphate 3-kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0000832; F:inositol hexakisphosphate 5-kinase activity; ISS:UniProtKB.
DR   GO; GO:0000828; F:inositol hexakisphosphate kinase activity; IDA:MGI.
DR   GO; GO:0000827; F:inositol-1,3,4,5,6-pentakisphosphate kinase activity; ISS:UniProtKB.
DR   GO; GO:0006020; P:inositol metabolic process; ISS:UniProtKB.
DR   GO; GO:0032958; P:inositol phosphate biosynthetic process; IBA:GO_Central.
DR   GO; GO:0043647; P:inositol phosphate metabolic process; TAS:Reactome.
DR   CDD; cd07061; HP_HAP_like; 1.
DR   Gene3D; 3.40.50.1240; -; 1.
DR   InterPro; IPR033379; Acid_Pase_AS.
DR   InterPro; IPR000560; His_Pase_clade-2.
DR   InterPro; IPR029033; His_PPase_superfam.
DR   Pfam; PF00328; His_Phos_2; 1.
DR   SUPFAM; SSF53254; SSF53254; 3.
DR   PROSITE; PS00616; HIS_ACID_PHOSPHAT_1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Cytoplasm; Kinase; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Transferase.
FT   CHAIN         1   1243       Inositol hexakisphosphate and
FT                                diphosphoinositol-pentakisphosphate
FT                                kinase 2.
FT                                /FTId=PRO_0000315692.
FT   NP_BIND     237    240       ATP. {ECO:0000244|PDB:3T54,
FT                                ECO:0000244|PDB:3T7A,
FT                                ECO:0000244|PDB:3T99,
FT                                ECO:0000244|PDB:3T9A,
FT                                ECO:0000244|PDB:3T9B,
FT                                ECO:0000244|PDB:3T9C,
FT                                ECO:0000244|PDB:3T9D,
FT                                ECO:0000244|PDB:3T9E,
FT                                ECO:0000244|PDB:3T9F,
FT                                ECO:0000269|PubMed:22119861}.
FT   NP_BIND     246    248       ATP. {ECO:0000244|PDB:3T54,
FT                                ECO:0000244|PDB:3T9A,
FT                                ECO:0000244|PDB:3T9B,
FT                                ECO:0000244|PDB:3T9C,
FT                                ECO:0000244|PDB:3T9D,
FT                                ECO:0000269|PubMed:22119861}.
FT   NP_BIND     321    323       ATP. {ECO:0000244|PDB:3T54,
FT                                ECO:0000269|PubMed:22119861}.
FT   REGION       53     54       Substrate binding. {ECO:0000244|PDB:3T9C,
FT                                ECO:0000244|PDB:3T9D,
FT                                ECO:0000244|PDB:3T9E,
FT                                ECO:0000244|PDB:3T9F,
FT                                ECO:0000269|PubMed:22119861}.
FT   REGION      213    214       Substrate binding. {ECO:0000244|PDB:3T9C,
FT                                ECO:0000244|PDB:3T9D,
FT                                ECO:0000244|PDB:3T9E,
FT                                ECO:0000244|PDB:3T9F,
FT                                ECO:0000269|PubMed:22119861}.
FT   REGION      326    329       Substrate binding. {ECO:0000244|PDB:3T9D,
FT                                ECO:0000244|PDB:3T9E,
FT                                ECO:0000269|PubMed:22119861}.
FT   REGION      371    442       Polyphosphoinositide-binding domain.
FT                                {ECO:0000269|PubMed:21222653}.
FT   BINDING     134    134       ATP. {ECO:0000244|PDB:3T54,
FT                                ECO:0000244|PDB:3T7A,
FT                                ECO:0000244|PDB:3T99,
FT                                ECO:0000244|PDB:3T9A,
FT                                ECO:0000244|PDB:3T9B,
FT                                ECO:0000244|PDB:3T9C,
FT                                ECO:0000244|PDB:3T9D,
FT                                ECO:0000244|PDB:3T9E,
FT                                ECO:0000244|PDB:3T9F,
FT                                ECO:0000269|PubMed:22119861}.
FT   BINDING     187    187       ATP. {ECO:0000244|PDB:3T54,
FT                                ECO:0000244|PDB:3T7A,
FT                                ECO:0000244|PDB:3T99,
FT                                ECO:0000244|PDB:3T9A,
FT                                ECO:0000244|PDB:3T9B,
FT                                ECO:0000244|PDB:3T9C,
FT                                ECO:0000244|PDB:3T9D,
FT                                ECO:0000244|PDB:3T9E,
FT                                ECO:0000244|PDB:3T9F,
FT                                ECO:0000269|PubMed:22119861}.
FT   BINDING     194    194       ATP. {ECO:0000244|PDB:3T54,
FT                                ECO:0000244|PDB:3T7A,
FT                                ECO:0000244|PDB:3T99,
FT                                ECO:0000244|PDB:3T9A,
FT                                ECO:0000244|PDB:3T9B,
FT                                ECO:0000244|PDB:3T9C,
FT                                ECO:0000244|PDB:3T9D,
FT                                ECO:0000244|PDB:3T9E,
FT                                ECO:0000244|PDB:3T9F,
FT                                ECO:0000269|PubMed:22119861}.
FT   BINDING     213    213       ATP. {ECO:0000244|PDB:3T9A,
FT                                ECO:0000244|PDB:3T9B,
FT                                ECO:0000244|PDB:3T9C,
FT                                ECO:0000244|PDB:3T9D,
FT                                ECO:0000269|PubMed:22119861}.
FT   BINDING     248    248       Substrate. {ECO:0000244|PDB:3T9C,
FT                                ECO:0000244|PDB:3T9D,
FT                                ECO:0000244|PDB:3T9E,
FT                                ECO:0000244|PDB:3T9F,
FT                                ECO:0000269|PubMed:22119861}.
FT   BINDING     262    262       Substrate. {ECO:0000244|PDB:3T9C,
FT                                ECO:0000244|PDB:3T9E,
FT                                ECO:0000244|PDB:3T9F,
FT                                ECO:0000269|PubMed:22119861}.
FT   BINDING     264    264       ATP. {ECO:0000244|PDB:3T54,
FT                                ECO:0000244|PDB:3T7A,
FT                                ECO:0000269|PubMed:22119861}.
FT   BINDING     309    309       ATP. {ECO:0000244|PDB:3T54,
FT                                ECO:0000244|PDB:3T7A,
FT                                ECO:0000244|PDB:3T99,
FT                                ECO:0000244|PDB:3T9B,
FT                                ECO:0000244|PDB:3T9C,
FT                                ECO:0000244|PDB:3T9D,
FT                                ECO:0000244|PDB:3T9E,
FT                                ECO:0000244|PDB:3T9F,
FT                                ECO:0000269|PubMed:22119861}.
FT   MOD_RES      38     38       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     223    223       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1006   1006       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1016   1016       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1074   1074       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1091   1091       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1165   1165       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1172   1172       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1180   1180       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1220   1220       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1221   1221       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ    1097   1117       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_030636.
FT   VARIANT     944    944       A -> G (in dbSNP:rs17155115).
FT                                /FTId=VAR_038276.
FT   VARIANT     985    985       E -> K (in dbSNP:rs12519525).
FT                                /FTId=VAR_038277.
FT   VARIANT    1003   1003       R -> K (in dbSNP:rs12520040).
FT                                /FTId=VAR_038278.
FT   VARIANT    1206   1206       P -> Q (in dbSNP:rs17155138).
FT                                /FTId=VAR_038279.
FT   VARIANT    1232   1232       T -> M (in dbSNP:rs17155147).
FT                                /FTId=VAR_038280.
FT   MUTAGEN     213    213       R->A,K: Reduces enzyme activity by about
FT                                99%. {ECO:0000269|PubMed:22119861}.
FT   MUTAGEN     248    248       K->A: Loss of enzyme activity.
FT                                {ECO:0000269|PubMed:22119861}.
FT   MUTAGEN     262    262       R->A: Reduces enzyme activity by about
FT                                99%. {ECO:0000269|PubMed:22119861}.
FT   STRAND       44     50       {ECO:0000244|PDB:3T7A}.
FT   HELIX        52     55       {ECO:0000244|PDB:3T7A}.
FT   HELIX        58     67       {ECO:0000244|PDB:3T7A}.
FT   STRAND       73     77       {ECO:0000244|PDB:3T7A}.
FT   HELIX        80     85       {ECO:0000244|PDB:3T7A}.
FT   HELIX        88     90       {ECO:0000244|PDB:3T7A}.
FT   STRAND       95     99       {ECO:0000244|PDB:3T7A}.
FT   HELIX       107    117       {ECO:0000244|PDB:3T7A}.
FT   STRAND      120    123       {ECO:0000244|PDB:3T7A}.
FT   HELIX       127    131       {ECO:0000244|PDB:3T7A}.
FT   HELIX       134    143       {ECO:0000244|PDB:3T7A}.
FT   STRAND      151    154       {ECO:0000244|PDB:3T7A}.
FT   STRAND      158    160       {ECO:0000244|PDB:4NZN}.
FT   HELIX       161    163       {ECO:0000244|PDB:3T7A}.
FT   STRAND      164    168       {ECO:0000244|PDB:3T7A}.
FT   STRAND      170    175       {ECO:0000244|PDB:3T7A}.
FT   STRAND      178    190       {ECO:0000244|PDB:3T7A}.
FT   STRAND      197    199       {ECO:0000244|PDB:3T7A}.
FT   HELIX       202    204       {ECO:0000244|PDB:3T7A}.
FT   STRAND      208    215       {ECO:0000244|PDB:3T7A}.
FT   STRAND      218    224       {ECO:0000244|PDB:3T7A}.
FT   STRAND      230    232       {ECO:0000244|PDB:3T7A}.
FT   STRAND      234    238       {ECO:0000244|PDB:3T7A}.
FT   STRAND      243    253       {ECO:0000244|PDB:3T7A}.
FT   STRAND      257    263       {ECO:0000244|PDB:3T7A}.
FT   STRAND      265    267       {ECO:0000244|PDB:3T9A}.
FT   STRAND      275    279       {ECO:0000244|PDB:3T9A}.
FT   HELIX       288    300       {ECO:0000244|PDB:3T7A}.
FT   STRAND      303    313       {ECO:0000244|PDB:3T7A}.
FT   STRAND      316    325       {ECO:0000244|PDB:3T7A}.
FT   HELIX       332    354       {ECO:0000244|PDB:3T7A}.
SQ   SEQUENCE   1243 AA;  140407 MW;  A8831DDDAB9B2E6E CRC64;
     MSEAPRFFVG PEDTEINPGN YRHFFHHADE DDEEEDDSPP ERQIVVGICS MAKKSKSKPM
     KEILERISLF KYITVVVFEE EVILNEPVEN WPLCDCLISF HSKGFPLDKA VAYAKLRNPF
     VINDLNMQYL IQDRREVYSI LQAEGILLPR YAILNRDPNN PKECNLIEGE DHVEVNGEVF
     QKPFVEKPVS AEDHNVYIYY PTSAGGGSQR LFRKIGSRSS VYSPESNVRK TGSYIYEEFM
     PTDGTDVKVY TVGPDYAHAE ARKSPALDGK VERDSEGKEV RYPVILNARE KLIAWKVCLA
     FKQTVCGFDL LRANGQSYVC DVNGFSFVKN SMKYYDDCAK ILGNIVMREL APQFHIPWSI
     PLEAEDIPIV PTTSGTMMEL RCVIAVIRHG DRTPKQKMKM EVRHQKFFDL FEKCDGYKSG
     KLKLKKPKQL QEVLDIARQL LMELGQNNDS EIEENKPKLE QLKTVLEMYG HFSGINRKVQ
     LTYLPHGCPK TSSEEEDSRR EEPSLLLVLK WGGELTPAGR VQAEELGRAF RCMYPGGQGD
     YAGFPGCGLL RLHSTYRHDL KIYASDEGRV QMTAAAFAKG LLALEGELTP ILVQMVKSAN
     MNGLLDSDSD SLSSCQQRVK ARLHEILQKD RDFTAEDYEK LTPSGSISLI KSMHLIKNPV
     KTCDKVYSLI QSLTSQIRHR MEDPKSSDIQ LYHSETLELM LRRWSKLEKD FKTKNGRYDI
     SKIPDIYDCI KYDVQHNGSL KLENTMELYR LSKALADIVI PQEYGITKAE KLEIAKGYCT
     PLVRKIRSDL QRTQDDDTVN KLHPVYSRGV LSPERHVRTR LYFTSESHVH SLLSILRYGA
     LCNESKDEQW KRAMDYLNVV NELNYMTQIV IMLYEDPNKD LSSEERFHVE LHFSPGAKGC
     EEDKNLPSGY GYRPASRENE GRRPFKIDND DEPHTSKRDE VDRAVILFKP MVSEPIHIHR
     KSPLPRSRKT ATNDEESPLS VSSPEGTGTW LHYTSGVGTG RRRRRSGEQI TSSPVSPKSL
     AFTSSIFGSW QQVVSENANY LRTPRTLVEQ KQNPTVGSHC AGLFSTSVLG GSSSAPNLQD
     YARTHRKKLT SSGCIDDATR GSAVKRFSIS FARHPTNGFE LYSMVPSICP LETLHNALSL
     KQVDEFLASI ASPSSDVPRK TAEISSTALR SSPIMRKKVS LNTYTPAKIL PTPPATLKST
     KASSKPATSG PSSAVVPNTS SRKKNITSKT ETHEHKKNTG KKK
//
